Cadena de suministros de vacunas, cadena de frío y logística

South Sudan: Fighting Malaria Person-by-Person in Bentiu

It is 7:30 in the morning and Paulino watches as four white Land Cruisers pull into the UN protection of civilians (PoC) site in Bentiu, South Sudan. He’s one of 210 community health workers congregated next to a Doctors Without Borders/Médecins Sans Frontières (MSF) clinic inside the crowded displaced persons camp, ready to respond to a devastating outbreak of malaria.
 
Undefined

More Needs to Be Done in Fighting Malaria, CDC Chief Says

The world has made remarkable progress against malaria in the past 10 to 15 years. Deaths have been cut by half. More people are getting treated. And research on an effective vaccine continues.
 
Yet more needs to be done.
 
Eighty percent of malaria cases and 78 percent of deaths occur in sub-Saharan Africa, according to the World Health Organization. Most of those who die are young children.
 
Undefined

ACERCA DE LA BIBLIOTECA DE RECURSOS



Bienvenido a la biblioteca de recursos de la Red IAIM, una colección de publicaciones, capacitaciones, y herramientas relacionadas con la inmunización. La siguiente tabla muestra las siete categorías principales en las que han sido organizados los documentos, así como sus subcategorías. Por favor haga clic en el título de su interés, y se le llevará a una página donde se puede leer la información general sobre el tema y acceder a las publicaciones, capacitaciones, y herramientas específicas para ese tema.

Spanish

FDA begging manufacturers to participate in global single audit pilot program

The international Medical Device Single Audit Program (MDSAP) to coordinate manufacturing facility inspections across 5 countries is not securing much participation from industry, much to the chagrin of the FDA. Only 45 manufacturing sites expressed interest in joining the program in its first year, out of a goal of 330 sites by the end of 2016.
 
Undefined

With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs

Back in June, the CDC's Advisory Committee on Immunization Practices (ACIP) widened its recommendation for meningitis B vaccines--but stopped short of recommending routine immunization. Instead, it left the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.
 
Undefined

Pertussis Passed to Newborns From Siblings

A new study has found that siblings, not mothers, are now the most common source of pertussis infection in newborns.
 
Infants can be given the DTaP vaccine (it also protects against tetanus and diphtheria) starting at 2 months, and the schedule calls for four more shots periodically through ages 4 to 6.
 
Undefined

MSF warns that Sanofi leaving antivenom market will lead to treatment crisis

Sanofi Pasteur says it let the world know 5 years ago that it would quit making Fav-Afrique, a snakebite antivenom, because cheaper products had left it unable to compete. But Doctors Without Borders this week said the other products are not as effective and said an impending shortage will lead to unnecessary deaths, often of children.
 
Undefined

Sierra Leone News: Sustainable Immunization symposium ends

Sustainable immunization Financing (SIF) is an initiative of the Sabin Vaccine Institute, which is an advocacy programme that helps countries finding long-term reliable financing for their national immunization programme.
 
SIF works with key national decision-makers to find ways to increase domestic immunization funding and lessen dependency on outside donors and partners.
 
Undefined

Dengue fever: How a mosquito infected millions, and not with malaria

A bite from a single mosquito can result in fever, headaches, and pain. Severe cases can experience a multitude of symptoms including bleeding, shock, organ failure -- and potentially death.
 
There is no treatment or vaccine and no real means of protecting yourself in countries endemic for the disease.
 
Though affected countries were once few, today more than 100 harbor the risk of infection -- putting more than half the world's population at risk and resulting in 50 million infections each year.
 
Undefined

L’inquiétante pénurie de l’anti-venin FAV-Afrique

C’est un outil précieux que perdront les médecins africains fin 2016. A cette date, les derniers lots de FAV-Afrique, un sérum anti-venin très efficace contre la morsure de serpents, auront été épuisés. Et il n’y aura pas de nouvelle livraison : Sanofi, son inventeur, a arrêté en 2014 la fabrication, faute de clients. « Quand la décision a été prise en 2010, nous ne vendions plus que 5 000 doses contre 30 000 quelques années auparavant », explique Alain Bernal, porte-parole de Sanofi-Pasteur.
 
Undefined

Pages